SciDEX — P-TAU

Understanding Entity Pages

This page aggregates everything SciDEX knows about P-TAU: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

Outgoing (6)

Target	Relation	Type	Str
neuronal death	prevents	phenotype	0.93
Amyloid-Beta Pathophysiology	associated_with	process	0.85
NEURODEGENERATION	activates	phenotype	0.70
NEURODEGENERATION	interacts_with	phenotype	0.65
ALZHEIMER	biomarker_for	disease	0.65
APOPTOSIS	activates	phenotype	0.65

Incoming (23)

Source	Relation	Type	Str
quinic acid	decreases	compound	0.80
APOE	produces	gene	0.70
TAU	phosphorylates	protein	0.65
ATG5	degrades	gene	0.65
ATG5	inhibits	gene	0.65
ATG5	activates	gene	0.65
ATG5	treats	gene	0.65
AUTOPHAGY	exacerbates	phenotype	0.65
CSF	synergizes_with	phenotype	0.60
AUTOPHAGY	implicated_in	phenotype	0.55
EXOSOME	associated_with	organelle	0.50
FDG-PET	associated_with	biomarker	0.50
CSF	associated_with	phenotype	0.50
ENTORHINAL CORTEX	associated_with	brain_region	0.50
CORTEX	associated_with	brain_region	0.50
INSULIN SIGNALING	associated_with	pathway	0.50
TREHALOSE	associated_with	drug	0.50
HIPPOCAMPUS	associated_with	brain_region	0.50
GLIAL FIBRILLARY ACIDIC PROTEIN	associated_with	biomarker	0.45
NEUROFILAMENT LIGHT	associated_with	biomarker	0.45
METFORMIN	associated_with	drug	0.45
TEMPORAL LOBE	associated_with	brain_region	0.45
RAPAMYCIN	associated_with	drug	0.45

Hypothesis	Score	Disease	Analysis
Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00	0.589	molecular neurobiology	View

Hypothesis

Score

Disease

Analysis

Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-00

0.589

molecular neurobiology

View

Mentioning Analyses (6)

Scientific analyses that reference this entity

What are the specific molecular determinants that govern tau strain selection du

neurodegeneration | 2026-04-15 | 2 hypotheses Top: 0.636

Do P2RX7 antagonists selectively block pathogenic exosomes while preserving bene

neurodegeneration | 2026-04-11 | 0 hypotheses

How can ESCRT or SNARE targeting achieve tau-specific effects without disrupting

molecular biology | 2026-04-08 | 0 hypotheses

Which tau propagation mechanism predominates in different brain regions and dise

neurodegeneration | 2026-04-07 | 0 hypotheses

Can chaperone enhancement approaches overcome tau seed saturation effects in adv

protein folding | 2026-04-06 | 0 hypotheses

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Experiment

Type

Disease

Score

Feasibility

Model

Status

Est. Cost

No experiments found

Title & PMID	Authors	Journal	Year	Citations
No papers found

Title & PMID

Authors

Journal

Year

Citations

No papers found

P-TAU

Understanding Entity Pages

Wiki Pages (21)

CTAD 2025 Conference

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Novel Therapy Index

Atypical Parkinsonism

nhp-validation-animal-model

Alzheimer's Disease

Outgoing (6)

Incoming (23)

Targeting Hypotheses (1)

Mentioning Analyses (6)

What are the specific molecular determinants that govern tau strain selection du

Do P2RX7 antagonists selectively block pathogenic exosomes while preserving bene

How can ESCRT or SNARE targeting achieve tau-specific effects without disrupting

Which tau propagation mechanism predominates in different brain regions and dise

Can chaperone enhancement approaches overcome tau seed saturation effects in adv

What is the therapeutic window between tau propagation inhibition and essential

Experiments (0)

Related Papers (0)

Debates (2)

The debate highlighted tau prion-like transmission but did not resolve how diffe

The debate identified fundamental druggability challenges for these targets due

P-TAU

Understanding Entity Pages

Wiki Pages (21)

CTAD 2025 Conference

Personalized Treatment Plan — Atypical Parkinsonism (CBS/PSP)

Novel Therapy Index

Atypical Parkinsonism

nhp-validation-animal-model

Alzheimer's Disease

Frontotemporal Dementia (FTD)

p-tau-217

Tau Spreading Mechanism

oxidative-stress-comparison

ftd-tdp-pathology

Prion vs Tau/Alpha-Synuclein Propagation: Mechanistic Comparison

Axonal Transport Dysfunction Comparison Across Neurodegenerative Diseases

AI and Machine Learning in Neurodegeneration

Vascular Cognitive Impairment (VCI)

Sulforaphane and Nrf2 Activation for Neuroprotection

Lithium for PSP/CBS — Phase 2 Trial

CSF Neurofilament Light Chain (NfL) in Neurodegeneration

A Phase 3, Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Tolerability, and Safety of Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease

Traumatic Brain Injury and Neurodegeneration Pathway

Excitotoxicity in Neurodegeneration

Outgoing (6)

Incoming (23)

Targeting Hypotheses (1)

Mentioning Analyses (6)

What are the specific molecular determinants that govern tau strain selection du

Do P2RX7 antagonists selectively block pathogenic exosomes while preserving bene

How can ESCRT or SNARE targeting achieve tau-specific effects without disrupting

Which tau propagation mechanism predominates in different brain regions and dise

Can chaperone enhancement approaches overcome tau seed saturation effects in adv

What is the therapeutic window between tau propagation inhibition and essential

Experiments (0)

Related Papers (0)

Debates (2)

The debate highlighted tau prion-like transmission but did not resolve how diffe

The debate identified fundamental druggability challenges for these targets due